Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › STEP UP

STEP UP

Semaglutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
obesity
Official title
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
Sponsor
Novo Nordisk A/S
Phase
3
Registry status
completed · 2023-01 → 2024-10
Participants
1407
Duration
72 weeks
Registry
NCT05646706

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
semaglutide 7.2 mgobesity721407−20.7 % vs −2.4 %
Δ −18.3 pp
−18.7 % vs −3.9 %
Δ −14.8 pp
−0.3 vs −0.05.4 vs 1.011.6 vs 29.4——6.8 vs 5.5−9.9 vs −4.4verified
semaglutide 2.4 mgobesity721407−17.5 % vs −2.4 %
Δ −15.1 pp
−15.6 % vs −3.9 %
Δ −11.7 pp
−0.3 vs −0.04.0 vs 1.011.9 vs 29.4——10.9 vs 5.5−8.7 vs −4.4verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (12)
  • semaglutide 7.2 mg · weight_eff · Results, paragraph 3; Figure 2B
    Using the trial product estimand, the mean change in bodyweight was –20·7% (SE 0·3) with semaglutide 7·2 mg
  • semaglutide 7.2 mg · weight_tp · Table 2
    –18·7% (0·4); n=950
  • semaglutide 7.2 mg · ae_dc · Results, safety paragraphs; Table 3
    Permanent discontinuation of the trial product occurred in 54 (5·4%) of 1004 participants receiving semaglutide 7·2 mg
  • semaglutide 7.2 mg · disc_any · Figure 1
    117 discontinued treatment
  • semaglutide 7.2 mg · sae · Results; Table 3
    Serious adverse events were reported by 68 (6·8%) of 1004 participants receiving semaglutide 7·2 mg
  • semaglutide 7.2 mg · hba1c · Table 2
    –0·32 (0·01); n=938
  • semaglutide 7.2 mg · sbp · Table 2
    –9·9 (0·4); n=949
  • semaglutide 2.4 mg · ae_dc · Results, Safety (text) + Table 3; safety set N=1004/201/201
    Permanent discontinuation of the trial product occurred in 54 (5·4%) of 1004 participants receiving semaglutide 7·2 mg, eight (4·0%) of 201 receiving semaglutide 2·4 mg, and two (1·0%) of 201 receiving placebo
  • semaglutide 2.4 mg · disc_any · Figure 1 trial profile
    24 discontinued treatment 8 adverse events
  • semaglutide 2.4 mg · sae · Results, Safety (text) + Table 3; safety set N=1004/201/201
    Serious adverse events were reported by 68 (6·8%) of 1004 participants receiving semaglutide 7·2 mg, 22 (10·9%) of 201 receiving semaglutide 2·4 mg, and 11 (5·5%) of 201 receiving placebo
  • semaglutide 2.4 mg · hba1c · Table 2 (supportive secondary)
    HbA1c, percentage points –0·32 (0·01); n=938 –0·30 (0·02); n=186 –0·02 (0·03); n=167
  • semaglutide 2.4 mg · sbp · Table 2 (supportive secondary, Blood pressure)
    Systolic –9·9 (0·4); n=949 –8·7 (1·0); n=188 –4·4 (0·8); n=171

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: STEP UP. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-up/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.